Woodline Partners LP Purchases 60,927 Shares of XOMA Co. (NASDAQ:XOMA)

Woodline Partners LP grew its position in shares of XOMA Co. (NASDAQ:XOMA - Free Report) by 63.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 156,266 shares of the biotechnology company's stock after acquiring an additional 60,927 shares during the period. Woodline Partners LP owned about 1.33% of XOMA worth $4,107,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. New York State Common Retirement Fund grew its holdings in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock worth $62,000 after acquiring an additional 800 shares during the period. Wells Fargo & Company MN grew its holdings in shares of XOMA by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after acquiring an additional 1,183 shares during the period. Bank of America Corp DE grew its holdings in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after acquiring an additional 2,009 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of XOMA during the 4th quarter worth approximately $206,000. Finally, Rhumbline Advisers grew its holdings in shares of XOMA by 18.1% during the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock worth $291,000 after acquiring an additional 1,699 shares during the period. Hedge funds and other institutional investors own 95.92% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on XOMA shares. Benchmark started coverage on XOMA in a research report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $104.00 price target on shares of XOMA in a research report on Wednesday. Finally, Wall Street Zen raised XOMA from a "sell" rating to a "hold" rating in a research report on Friday, April 11th.

Insider Activity at XOMA

In other XOMA news, CIO Bradley Sitko acquired 4,134 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were acquired at an average cost of $23.89 per share, with a total value of $98,761.26. Following the transaction, the executive now owns 10,484 shares of the company's stock, valued at $250,462.76. The trade was a 65.10% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the company's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the transaction, the insider now directly owns 1,267,545 shares in the company, valued at $34,350,469.50. This trade represents a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have acquired 29,312 shares of company stock valued at $735,061. 9.10% of the stock is owned by corporate insiders.

XOMA Stock Down 0.5%

Shares of XOMA traded down $0.12 during mid-day trading on Friday, reaching $25.39. The company had a trading volume of 1,264 shares, compared to its average volume of 30,861. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The firm has a 50-day moving average price of $22.85 and a 200 day moving average price of $25.14. XOMA Co. has a 52 week low of $18.35 and a 52 week high of $35.00. The company has a market capitalization of $303.78 million, a price-to-earnings ratio of -7.29 and a beta of 0.89.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.32. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $15.91 million for the quarter, compared to analysts' expectations of $6.75 million. On average, sell-side analysts forecast that XOMA Co. will post -1.41 EPS for the current year.

XOMA Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.